Optymalizacja i utrzymanie hemostazy

Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network

Źródło‎: N Engl J Med 2017;376(2):136-48.

Indeks‎: PubMed 27774838

DOI‎: 10.1056/NEJMoa1606424

http://www.ncbi.nlm.nih.gov/pubmed/27774838 (opens new window)

Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass. (opens new window)

Nurözler F, Kutlu T, Küçük G.

Źródło‎: Asian Cardiovasc Thorac Ann 2008;16(6):483-7.

Indeks‎: PubMed 18984759

DOI‎: 10.1177/021849230801600611

https://www.ncbi.nlm.nih.gov/pubmed/18984759 (opens new window)

Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. (opens new window)

Shi J, Ji H, Ren F, Wang G, Xu M, Xue Y, Chen M, Qi J, Li L.

Źródło‎: JAMA Surg 2013;148(6):538-47.

Indeks‎: PubMed 23426385

DOI‎: 10.1001/jamasurg.2013.1560

https://www.ncbi.nlm.nih.gov/pubmed/23426385 (opens new window)

Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: The OPTIMAL randomized clinical trial. (opens new window)

Shi J, Zhou C, Pan W, Sun H, Liu S, Feng W, Wang W, Cheng Z, Wang Y, Zheng Z

Źródło‎: JAMA. 2022;328(4):336-47.

Indeks‎: PubMed 35881121

DOI‎: 10.1001/jama.2022.10725

https://pubmed.ncbi.nlm.nih.gov/35881121/ (opens new window)

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study. (opens new window)

Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, Liu M, Chen L, Li L.

Źródło‎: Anesth Analg 2012;115(2):239-43.

Indeks‎: PubMed 21737704

DOI‎: 10.1213/ANE.0b013e3182264a11

https://www.ncbi.nlm.nih.gov/pubmed/21737704 (opens new window)

Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. (opens new window)

Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S.

Źródło‎: Ann Thorac Surg 2010;89(5):1489-95.

Indeks‎: PubMed 20417766

DOI‎: 10.1016/j.athoracsur.2010.02.006

https://www.ncbi.nlm.nih.gov/pubmed/20417766 (opens new window)

Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. (opens new window)

Øvrum E, Tangen G, Tølløfsrud S, Ringdal MA, Øystese R, Istad R.

Źródło‎: Interact Cardiovasc Thorac Surg 2010;10(4):545-8.

Indeks‎: PubMed 20067988

DOI‎: 10.1510/icvts.2009.226613

https://www.ncbi.nlm.nih.gov/pubmed/20067988 (opens new window)

Rekombinowany aktywowany czynnik VII (rFVIIa)

Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? (opens new window)

Ballen J, Raabe M, Muirhead B.

Źródło‎: Can J Anaesth 2006;53(4):353-6.

Indeks‎: PubMed 16575032

DOI‎: 10.1007/BF03022498

https://www.ncbi.nlm.nih.gov/pubmed/16575032 (opens new window)

Use of recombinant activated factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. (opens new window)

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Źródło‎: Transfusion 2013;53(4):798-804.

Indeks‎: PubMed 22845023

DOI‎: 10.1111/j.1537-2995.2012.03801.x

https://www.ncbi.nlm.nih.gov/pubmed/22845023 (opens new window)

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. (opens new window)

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Źródło‎: Ann Thorac Surg 2008;85(3):836-44.

Indeks‎: PubMed 18291152

DOI‎: 10.1016/j.athoracsur.2007.06.076

https://www.ncbi.nlm.nih.gov/pubmed/18291152 (opens new window)

Repeat cardiac surgery in a Jehovah's Witness patient with thrombocytopenia. (opens new window)

Elmistekawy E, Lapierre H, Bourke M, Dennie C, Labinaz M, Ruel M.

Źródło‎: Can J Cardiol 2011;27(6):869.e7-8.

Indeks‎: PubMed 21983113

DOI‎: 10.1016/j.cjca.2011.07.632

https://www.ncbi.nlm.nih.gov/pubmed/21983113 (opens new window)

Off-label use of recombinant activated factor VII for cardiac surgical bleeding. (opens new window)

Flynn BC, Steiner ME, Mazzeffi M

Źródło‎: Anesthesiology. 2023 1;139(2):197-210.

Indeks‎: PubMed 37155359

DOI‎: 10.1097/ALN.0000000000004569

https://pubmed.ncbi.nlm.nih.gov/37155359/ (opens new window)

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. (opens new window)

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Źródło‎: Circulation 2009;120(1):21-7.

Indeks‎: PubMed 19546387

DOI‎: 10.1161/CIRCULATIONAHA.108.834275

https://www.ncbi.nlm.nih.gov/pubmed/19546387 (opens new window)

Intraoperative use of recombinant activated factor VII during complex aortic surgery. (opens new window)

Goksedef D, Panagopoulos G, Nassiri N, Levine RL, Hountis PG, Plestis KA.

Źródło‎: J Thorac Cardiovasc Surg 2012;143(5):1198-204.

Indeks‎: PubMed 22285329

DOI‎: 10.1016/j.jtcvs.2012.01.004

https://www.ncbi.nlm.nih.gov/pubmed/22285329 (opens new window)

Off-label use of recombinant human factor VIIa. (opens new window)

Goodnough LT, Levy JH.

Źródło‎: Ann Thorac Surg 2014;98(2):393-5.

Indeks‎: PubMed 25087781

DOI‎: 10.1016/j.athoracsur.2014.06.007

https://www.ncbi.nlm.nih.gov/pubmed/25087781 (opens new window)

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). (opens new window)

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Źródło‎: Eur J Cardiothorac Surg 2011;40(6):1320-7.

Indeks‎: PubMed 21550261

DOI‎: 10.1016/j.ejcts.2011.03.032

https://www.ncbi.nlm.nih.gov/pubmed/21550261 (opens new window)

Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. (opens new window)

Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, Cheng D, Heinrich L, Kent B, Lee TW, MacAdams C, Mazer CD, Muirhead B, Rochon AG, Rubens FD, Sawchuk C, Wang S, Waters T, Wong BI, Yau TM.

Źródło‎: Circulation 2008;118(4):331-8.

Indeks‎: PubMed 18606914

DOI‎: 10.1161/CIRCULATIONAHA.108.764308

https://www.ncbi.nlm.nih.gov/pubmed/18606914 (opens new window)

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. (opens new window)

Končar IB, Davidović LB, Savić N, Sinđelić RB, Ilić N, Dragas M, Markovic M, Kostic D.

Źródło‎: J Vasc Surg 2011;53(4):1032-7.

Indeks‎: PubMed 21215579

DOI‎: 10.1016/j.jvs.2010.07.075

https://www.ncbi.nlm.nih.gov/pubmed/21215579 (opens new window)

Use of activated recombinant factor VII in severe bleeding—evidence for efficacy and safety in trauma, postpartum hemorrhage, cardiac surgery, and gastrointestinal bleeding. (opens new window)

Lau P, Ong V, Tan WT, Koh PL, Hartman M.

Źródło‎: Transfus Med Hemother 2012;39(2):139-50.

Indeks‎: PubMed 22670132

DOI‎: 10.1159/000338034

https://www.ncbi.nlm.nih.gov/pubmed/22670132 (opens new window)

Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection. (opens new window)

Lehr EJ, Alford TJ, Wang SH.

Źródło‎: Heart Surg Forum 2010;13(5):E275-9.

Indeks‎: PubMed 20961825

DOI‎: 10.1532/HSF98.20101027

https://www.ncbi.nlm.nih.gov/pubmed/20961825 (opens new window)

Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. (opens new window)

Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG.

Źródło‎: J Cardiothorac Vasc Anesth 2009;23(1):28-33.

Indeks‎: PubMed 18948033

DOI‎: 10.1053/j.jvca.2008.08.003

https://www.ncbi.nlm.nih.gov/pubmed/18948033 (opens new window)

Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. (opens new window)

Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM.

Źródło‎: Drugs R D 2015;15(2):187-94.

Indeks‎: PubMed 25862216

DOI‎: 10.1007/s40268-015-0093-9

https://www.ncbi.nlm.nih.gov/pubmed/25862216 (opens new window)

Hemostatic management of severe thrombocytopenia in a patient undergoing pulmonic valve replacement. (opens new window)

Tanaka KA, Li P, McHugh SM, Subramaniam K.

Źródło‎: A A Case Rep 2015;5(1):3-5.

Indeks‎: PubMed 26125690

DOI‎: 10.1213/XAA.0000000000000166

https://www.ncbi.nlm.nih.gov/pubmed/26125690 (opens new window)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (opens new window)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Źródło‎: Anesthesiology 2003;98(6):1513-5.

Indeks‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (opens new window)

Recombinant activated factor VII in cardiac surgery: a systematic review. (opens new window)

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T.

Źródło‎: Ann Thorac Surg 2007;83(2):707-14.

Indeks‎: PubMed 17258029

DOI‎: 10.1016/j.athoracsur.2006.10.033

https://www.ncbi.nlm.nih.gov/pubmed/17258029 (opens new window)

Koncentraty czynników krzepnięcia

Reduced use of allogeneic platelets through high-yield perioperative autologous plateletpheresis and reinfusion. (opens new window)

Alberts M, Bandarenko N, Gaca J, Lockhart E, Milano C, Alexander S, Linder D, Lombard FW, Welsby IJ.

Źródło‎: Transfusion 2014;54(5):1348-57.

Indeks‎: PubMed 24898456

DOI‎: 10.1111/trf.12463

https://www.ncbi.nlm.nih.gov/pubmed/24898456 (opens new window)

Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. (opens new window)

Arnékian V, Camous J, Fattal S, Rézaiguia-Delclaux S, Nottin R, Stéphan F.

Źródło‎: Interact Cardiovasc Thorac Surg 2012;15(3):382-9.

Indeks‎: PubMed 22623627

DOI‎: 10.1093/icvts/ivs224

https://www.ncbi.nlm.nih.gov/pubmed/22623627 (opens new window)

Reducing blood transfusion in aortic surgery: a novel approach. (opens new window)

Birla R, Nawaytou O, Shaw M, Jackson A, Mills K, Kuduvalli M, Field M, Agarwal S

Źródło‎: Ann Thorac Surg 2019;108(5):1369-75.

Indeks‎: PubMed 31255616

DOI‎: 10.1016/j.athoracsur.2019.04.127

https://www.ncbi.nlm.nih.gov/pubmed/31255616 (opens new window)

Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. (opens new window)

Bolliger D, Sreeram G, Duncan A, Molinaro RJ, Szlam F, Chen EP, Tanaka KA.

Źródło‎: Ann Thorac Surg 2009;88(5):1666-8.

Indeks‎: PubMed 19853132

DOI‎: 10.1016/j.athoracsur.2009.03.095

https://www.ncbi.nlm.nih.gov/pubmed/19853132 (opens new window)

Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. (opens new window)

Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M, Crosta S, Banescu S, Ahmed AB, Beghi C.

Źródło‎: Crit Care 2016;20:5.

Indeks‎: PubMed 26738468

DOI‎: 10.1186/s13054-015-1172-6

https://www.ncbi.nlm.nih.gov/pubmed/26738468 (opens new window)

Bloodless orthotopic heart transplantation in a Jehovah's Witness. (opens new window)

Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N.

Źródło‎: A A Case Rep 2015;4(10):140-2.

Indeks‎: PubMed 25974419

DOI‎: 10.1213/XAA.0000000000000067

https://www.ncbi.nlm.nih.gov/pubmed/25974419 (opens new window)

State of the art - how I manage coagulopathy in cardiac surgery patients. (opens new window)

Davidson S.

Źródło‎: Br J Haematol 2014;164(6):779-89.

Indeks‎: PubMed 24450971

DOI‎: 10.1111/bjh.12746

https://www.ncbi.nlm.nih.gov/pubmed/24450971 (opens new window)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (opens new window)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Źródło‎: Anesthesiology 2011;115(6):1179-91.

Indeks‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (opens new window)

Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. (opens new window)

Karkouti K, Bartoszko J, Grewal D, Bingley C, Armali C, Carroll J, Hucke HP, Kron A, McCluskey SA, Rao V, Callum J

Źródło‎: JAMA Netw Open 2021;4(4):e213936.

Indeks‎: PubMed 33792729

DOI‎: 10.1001/jamanetworkopen.2021.3936

https://www.ncbi.nlm.nih.gov/pubmed/33792729 (opens new window)

Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. (opens new window)

Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A.

Źródło‎: Thromb Haemost 2009;102(1):137-44.

Indeks‎: PubMed 19572078

DOI‎: 10.1160/TH08-09-0587

https://www.ncbi.nlm.nih.gov/pubmed/19572078 (opens new window)

Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. (opens new window)

Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M.

Źródło‎: J Thorac Cardiovasc Surg 2013;145(3 Suppl):S178-85.

Indeks‎: PubMed 23410777

DOI‎: 10.1016/j.jtcvs.2012.12.083

https://www.ncbi.nlm.nih.gov/pubmed/23410777 (opens new window)

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. (opens new window)

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Źródło‎: Anesthesiology 2013;118(1):40-50.

Indeks‎: PubMed 23249928

DOI‎: 10.1097/ALN.0b013e3182715d4d

https://www.ncbi.nlm.nih.gov/pubmed/23249928 (opens new window)

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. (opens new window)

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Źródło‎: J Am Heart Assoc 2015;4(6):e002066.

Indeks‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

https://www.ncbi.nlm.nih.gov/pubmed/26037084 (opens new window)

Fibrinogen supplementation after cardiac surgery: insights from the zero-plasma trial (ZEPLAST). (opens new window)

Ranucci M, Baryshnikova E.

Źródło‎: Br J Anaesth 2016;116(5):618-23.

Indeks‎: PubMed 26893405

DOI‎: 10.1093/bja/aev539

https://www.ncbi.nlm.nih.gov/pubmed/26893405 (opens new window)

Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate. (opens new window)

Robblee JA, Wilkes PR, Dickie SJ, Rubens FD, Bormanis J.

Źródło‎: Can J Anaesth 2012;59(3):299-303.

Indeks‎: PubMed 22161243

DOI‎: 10.1007/s12630-011-9647-7

https://www.ncbi.nlm.nih.gov/pubmed/22161243 (opens new window)

Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. (opens new window)

Roman M, Biancari F, Ahmed AB, Agarwal S, Hadjinikolaou L, Al-Sarraf A, Tsang G, Oo AY, Field M, Santini F, Mariscalco G

Źródło‎: Ann Thorac Surg 2019;107(4):1275-83.

Indeks‎: PubMed 30458156

DOI‎: 10.1016/j.athoracsur.2018.10.013

https://www.ncbi.nlm.nih.gov/pubmed/30458156 (opens new window)

Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. (opens new window)

Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA.

Źródło‎: Anesth Analg 2007;104(4):763-5.

Indeks‎: PubMed 17377078

DOI‎: 10.1213/01.ane.0000250913.45299.f3

https://www.ncbi.nlm.nih.gov/pubmed/17377078 (opens new window)

Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. (opens new window)

Solomon C, Schöchl H, Hanke A, Calatzis A, Hagl C, Tanaka K, Rahe-Meyer N.

Źródło‎: Scand J Clin Lab Invest 2012;72(2):121-8.

Indeks‎: PubMed 22233480

DOI‎: 10.3109/00365513.2011.643818

https://www.ncbi.nlm.nih.gov/pubmed/22233480 (opens new window)

Desmopresyna

Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry. (opens new window)

Hanke AA, Dellweg C, Kienbaum P, Weber CF, Görlinger K, Rahe-Meyer N.

Źródło‎: Anaesthesia 2010;65(7):688-91.

Indeks‎: PubMed 20477783

DOI‎: 10.1111/j.1365-2044.2010.06367.x

https://www.ncbi.nlm.nih.gov/pubmed/20477783 (opens new window)

Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. (opens new window)

Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG.

Źródło‎: J Cardiothorac Vasc Anesth 2007;21(6):851-4.

Indeks‎: PubMed 18068065

DOI‎: 10.1053/j.jvca.2007.05.009

https://www.ncbi.nlm.nih.gov/pubmed/18068065 (opens new window)

Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. (opens new window)

Wademan BH, Galvin SD.

Źródło‎: Interact Cardiovasc Thorac Surg 2014;18(3):360-70.

Indeks‎: PubMed 24263581

DOI‎: 10.1093/icvts/ivt491

https://www.ncbi.nlm.nih.gov/pubmed/24263581 (opens new window)

A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. (opens new window)

Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jámbor C.

Źródło‎: Anesth Analg 2010;110(3):702-7.

Indeks‎: PubMed 20042444

DOI‎: 10.1213/ANE.0b013e3181c92a5c

https://www.ncbi.nlm.nih.gov/pubmed/20042444 (opens new window)

Środki hemostatyczne o działaniu miejscowym

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. (opens new window)

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Źródło‎: Ann Surg 2010;251(2):217-28.

Indeks‎: PubMed 20010084

DOI‎: 10.1097/SLA.0b013e3181c3bcca

https://www.ncbi.nlm.nih.gov/pubmed/20010084 (opens new window)

A review of topical hemostatic agents for use in cardiac surgery. (opens new window)

Barnard J, Millner R.

Źródło‎: Ann Thorac Surg 2009;88(4):1377-83.

Indeks‎: PubMed 19766855

DOI‎: 10.1016/j.athoracsur.2009.02.092

https://www.ncbi.nlm.nih.gov/pubmed/19766855 (opens new window)

Armentarium of topical hemostatic products in cardiovascular surgery: an update. (opens new window)

Forcillo J, Perrault LP.

Źródło‎: Transfus Apher Sci 2014;50(1):26-31.

Indeks‎: PubMed 24412443

DOI‎: 10.1016/j.transci.2013.12.009

https://www.ncbi.nlm.nih.gov/pubmed/24412443 (opens new window)

A novel reverse thermosensitive polymer to achieve temporary atraumatic vessel occlusion in infra-popliteal bypasses. (opens new window)

Mani K, Campbell A, Fitzpatrick J, Modarai B, Carrell T, Rashid H, Zayed H.

Źródło‎: Eur J Vasc Endovasc Surg 2013;45(1):51-6.

Indeks‎: PubMed 23134676

DOI‎: 10.1016/j.ejvs.2012.10.008

https://www.ncbi.nlm.nih.gov/pubmed/23134676 (opens new window)

Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. (opens new window)

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N.

Źródło‎: Innovations (Phila) 2012;7(4):229-41.

Indeks‎: PubMed 23123988

DOI‎: 10.1097/IMI.0b013e3182747699

https://www.ncbi.nlm.nih.gov/pubmed/23123988 (opens new window)

Control of troublesome bleeding during repair of acute type A dissection with use of modified rapid deployment hemostat (MRDH). (opens new window)

Salerno TA, Gaughan C, Suarez M, Panos AL.

Źródło‎: J Card Surg 2009;24(6):722-4.

Indeks‎: PubMed 20078720

DOI‎: 10.1111/j.1540-8191.2009.00915.x

https://www.ncbi.nlm.nih.gov/pubmed/20078720 (opens new window)

Topical haemostatic agents. (opens new window)

Seyednejad H, Imani M, Jamieson T, Seifalian AM.

Źródło‎: Br J Surg 2008;95(10):1197-225.

Indeks‎: PubMed 18763249

DOI‎: 10.1002/bjs.6357

https://www.ncbi.nlm.nih.gov/pubmed/18763249 (opens new window)

Badania różnicujące krwawienie chirurgiczne z krwawieniem z koagulopatii (TEG)

An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. (opens new window)

Anderson L, Quasim I, Soutar R, Steven M, Macfie A, Korte W.

Źródło‎: Transfus Med 2006;16(1):31-9.

Indeks‎: PubMed 16480437

DOI‎: 10.1111/j.1365-3148.2006.00645.x

https://www.ncbi.nlm.nih.gov/pubmed/16480437 (opens new window)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (opens new window)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Źródło‎: Anesthesiology 2011;115(6):1179-91.

Indeks‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (opens new window)

Management of hemorrhage in cardiothoracic surgery. (opens new window)

Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA.

Źródło‎: J Cardiothorac Vasc Anesth 2013;27(4 Suppl):S20-34.

Indeks‎: PubMed 23910533

DOI‎: 10.1053/j.jvca.2013.05.014

https://www.ncbi.nlm.nih.gov/pubmed/23910533 (opens new window)

Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. (opens new window)

Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K.

Źródło‎: Anesthesiology 2012;117(3):531-47.

Indeks‎: PubMed 22914710

DOI‎: 10.1097/ALN.0b013e318264c644

https://www.ncbi.nlm.nih.gov/pubmed/22914710 (opens new window)

KARDIO-TORAKOCHIRURGIA I CHIRURGIA NACZYNIOWA

Optymalizacja i utrzymanie hemostazy

polski

Optymalizacja i utrzymanie hemostazy

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Środki antyfibrynolityczne

Rekombinowany aktywowany czynnik VII (rFVIIa)

Koncentraty czynników krzepnięcia

Desmopresyna

Środki hemostatyczne o działaniu miejscowym

Badania różnicujące krwawienie chirurgiczne z krwawieniem z koagulopatii (TEG)

Wybierz swój język

Udostępnij